Talazoparib + avelumab for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Sep 2016: Trial registered, NCT02912572
  2. 14 Nov 2016: Trial started, NCT02912572

The trials

NCT02912572: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

State
Under way
Phase
Phase 2
People
106 taking part
Started
14 Nov 2016
Primary completion
15 Nov 2023
Arms
MSS Avelumab/Talazoparib Combination Arm
Results
Posted on the registry
  1. 23 Sep 2016: Trial registered
  2. 14 Nov 2016: Trial started
  3. 5 Jul 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.